Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX's Pre-IPO and...
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On June 8, 2026, the Company issued to this employee an option to purchase an aggregate of 6,100 shares of the Company’s common stock with an exercise price of $5.86, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on June 8, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the option will be fully vested on June 8, 2030. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a publicly traded special purpose acquisition company.
In 2026 Morvulikent has officially announced the launch of its new AI-powered trading platform, introducing a next-generation automated trading environment designed to simplify financial market participation through artificial intelligence, real-time data analysis, and intelligent automation.
SHERIDAN, Wyo., June 12, 2026 /PRNewswire/ -- According to a new study by Wissen Research, the global sustainable pharmaceutical packaging market is projected to...
Nordstrom, Inc. and Master Perfumer Honorine Blanc Receive Industry's Top Honors-Ceremony Pays Tribute to Legends Lost - Giorgio Armani and Valentino GaravaniNEW YORK, June 11, 2026 /PRNewswire/...
NEWARK, Del., June 11, 2026 /PRNewswire/ -- The global folding IBC market is witnessing remarkable growth as industries increasingly adopt returnable bulk packaging solutions to...
TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...
CHICAGO, June 10, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, along with Morningstar, a leading provider of independent investment insights, today...
Rising adoption of AI, IoT, 5G, cloud computing, and real-time applications continues to drive investments in distributed computing infrastructure worldwide.SAN FRANCISCO, June 10, 2026...